Nicotinamide Phosphoribosyltransferase Pipeline Review, H2 2020 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

The latest report Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2020, outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects.

Key Topics Covered:

Introduction

• Report Coverage

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Overview

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Development

• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Assessment

• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Companies Involved in Therapeutics Development

• AbbVie Inc
• Aqualung Therapeutics Corp
• Aurigene Discovery Technologies Ltd
• Calico LLC
• Eli Lilly and Co
• Genentech USA Inc
• Karyopharm Therapeutics Inc
• OncoTartis Inc
• Tianjin Hemay Pharmaceutical Co Ltd

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Drug Profiles

ALT-200 - Drug Profile

AU-4869 - Drug Profile

enamptcumab - Drug Profile

GNE-617 - Drug Profile

Hemay-088 - Drug Profile

KPT-9274 - Drug Profile

LSN-3154567 - Drug Profile

OT-82 - Drug Profile

P7-C3A20 - Drug Profile

Small Molecules to Inhibit NAMPT for Oncology - Drug Profile

STF-118804 - Drug Profile

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Dormant Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Discontinued Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Product Development Milestones

• Featured News & Press Releases
• Oct 19, 2020: Researchers discover neuroprotective treatment for chronic traumatic brain injury
• Jun 02, 2020: Aqualung Therapeutics receives A $2.3 million National Institute Of Health (NIH) Fast-Track award to develop a novel therapeutic antibody for patients with radiation-induced lung injury
• May 27, 2020: Aqualung Therapeutics receives NIH approval to advance to IND-enabling studies via the STTR Fastrack Phase II award for development of a novel anti-inflammatory therapeutic antibody for ARDS and the critically ill
• Apr 13, 2020: Antengene announces dosing of first patient in the ATG-019 (KPT-9274) phase 1 trial, a first-in-class dual inhibitor, for advanced solid tumors and non-hodgkin's lymphoma
• Mar 18, 2020: Aqualung Therapeutics advances its investigational monoclonal antibody into IND-enabling studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)
• Jan 16, 2020: International research collaboration reveals promising drug candidate for treatment of blood cancers
• Dec 05, 2019: Aqualung Therapeutics to present new data at Biotech Showcase Investor Conference
• Aug 20, 2019: Aqualung Therapeutics receives $225 thousand dollar National Institute of Health (NIH) grant to establish biomarker panel for patients with acute respiratory distress syndrome
• Aug 13, 2019: Aqualung Therapeutics submits patent application to USPTO
• Aug 06, 2019: Aqualung Therapeutics filed patent for eNamptor
• Jul 20, 2019: Aqualung Therapeutics provides update on eNamptor
• Jul 13, 2019: Aqualung Therapeutics submits $3 million Department of Defense grant for eNamptor
• Jun 05, 2019: Aqualung Therapeutics receives a $1.7 Million National Institute Of Health (NIH) Fastrack Award To develop an novel immune-based therapeutic antibody for critically ill patients with acute lung injury
• Jun 04, 2019: Aqualung Therapeutics Corporation receives A $1.7 million National Institute of Health (NIH) fastrack award to develop an novel immune-based therapeutic antibody for critically Ill patients with acute lung injury
• Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hwfhf2